Abionyx Pharma

609

Company Profile

  • Business description

    Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.

  • Contact

    33-43 Avenue Georges Pompidou-Bat D2
    Balma31130
    FRA

    T: +33 562249706

    https://www.abionyx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    61

Stocks News & Analysis

stocks

Is CSL undervalued after earnings season wobble?

The ASX's biggest healthcare name saw its shares fall after reporting first-half results.
stocks

After earnings is Apple stock a buy, sell or fairly valued?

Our thoughts on Apple's stock amid slowing iPhone sales but high services revenue.
stocks

Competition impacting ASX market darling

Shares tumble after results.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,799.6048.000.55%
CAC 408,028.9022.680.28%
DAX 4022,037.83126.090.58%
Dow JONES (US)44,593.65123.240.28%
FTSE 1008,777.399.590.11%
HKSE21,677.73382.871.80%
NASDAQ19,643.8670.41-0.36%
Nikkei 22538,963.70162.530.42%
NZX 50 Index12,913.953.50-0.03%
S&P 5006,068.502.060.03%
S&P/ASX 2008,535.3051.300.60%
SSE Composite Index3,325.787.720.23%

Market Movers